Multiple Myeloma
News
Daratumumab approved in combo with VTd for transplant-eligible multiple myeloma
This marks the drug’s second approved indication this year and its seventh overall.
Conference Coverage
Subcutaneous and IV daratumumab combos appear comparable in myeloma
BOSTON – Response rates observed with subcutaneous daratumumab–based combinations in the PLEIADES trial were similar to rates observed with...
Conference Coverage
Quadruplet prolongs progression-free survival in newly diagnosed myeloma
BOSTON – Carfilzomib plus cyclophosphamide, lenalidomide, and dexamethasone significantly prolonged progression-free survival, compared with two...
Conference Coverage
Oral triplet shows promise for relapsed/refractory myeloma
BOSTON – Selinexor plus lenalidomide and dexamethasone proved particularly active in lenalidomide-naive patients.
Conference Coverage
Combo could be new standard for transplant-eligible, newly diagnosed myeloma patients
BOSTON – Adding daratumumab to bortezomib, lenalidomide, and dexamethasone improved responses and minimal residual disease negativity.
Conference Coverage
Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myeloma
BOSTON – The overall survival advantage with elotuzumab was observed in all prespecified patient subgroups, including older patients, those with...
Conference Coverage
CT103A elicits responses after prior CAR T-cell relapse
BOSTON – Three of four patients who had failed a prior CAR T-cell therapy achieved a stringent complete response after CT103A.
Conference Coverage
Melflufen-dexamethasone active in patients with relapsed/refractory myeloma and EMD
BOSTON – Melflufen plus dexamethasone produced similar response rates in patients with and without extramedullary disease.
From the Journals
VRD pretransplant induction deepens responses in myeloma
The researchers wrote that the unique dosing of the three-drug induction regimen may be considered a new standard of care.
From the Journals
Progressive myeloma after induction? Go straight to transplant
The study did not find a survival advantage for patients who had salvage therapy to deepen their responses before moving on to transplant.
From the Journals
Combo produces responses in triple-class refractory myeloma
Selinexor plus low-dose dexamethasone produced a response rate of 26% in patients who were refractory to at least one proteasome inhibitor, one...